Search details
1.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Lancet Oncol
; 15(7): 747-56, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24794243
2.
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
Breast Cancer Res Treat
; 124(1): 133-40, 2010 Nov.
Article
in English
| MEDLINE | ID: mdl-20697801
3.
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
J Clin Oncol
; 32(29): 3212-20, 2014 Oct 10.
Article
in English
| MEDLINE | ID: mdl-25199759
4.
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Eur J Cancer
; 49(10): 2284-93, 2013 Jul.
Article
in English
| MEDLINE | ID: mdl-23541564
5.
Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.
PLoS One
; 7(10): e45826, 2012.
Article
in English
| MEDLINE | ID: mdl-23056218
6.
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
J Clin Oncol
; 29(16): 2150-7, 2011 Jun 01.
Article
in English
| MEDLINE | ID: mdl-21519019
Results
1 -
6
de 6
1
Next >
>>